Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
For type 2 diabetes management , NICE guideline NG28 recommends considering GLP-1 receptor agonists when: Triple therapy with metformin and two other oral medications is ineffective, not tolerated or contraindicated The patient has a body mass index (BMI) of 35 kg/m or higher (with lower thresholds for people from certain ethnic backgrounds), or lower BMI with specific clinical circumstances where weight loss would benefit other obesity-related comorbidities Insulin would have significant occupational implications GLP-1 therapy should only be continued beyond six months if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0 percentage point) and weight loss of at least 3% of initial body weight
But the risks were tolerable, and the market too small to trigger regulators
1 Benefits may be dosage and application dependent
However, the confidence interval for this difference was 5.8 mmHg to 0.1 mmHg, suggesting that the statistical significance of this effect is borderline
While GLP-1 medications aid weight loss, lifestyle habits remain essential for sustained success
US$ 20.03
US$ 22.45
US$ 27.63
US$ 22.52
